Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
UROPLASTY INC (UPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/31/2015 8-K Form 8-K - Current report
03/10/2015 8-K Investor presentation
Docs: "AUA/SUFU Overactive Bladder Treatment Guideline"
03/03/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "MINNEAPOLIS, March 3, 2015 -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty’s corporate headquarters in Minnetonka, Minnesota. Rob Kill, President and Chief Executive Officer, will host the meeting, which will feature a discussion of the proposed merger between Uroplasty and Vision-Sciences and a presentation by Dr. Roland Ugarte, who will discuss the roles that Urgent PC and EndoSheath have in today’s urology practices. Dr. Ugarte is a Senior Partner of Urology Associates, a Minneapolis-based group of 15 urologic surgeons providing comprehensive care to over 75,000 ..."
01/27/2015 8-K Other Events
01/22/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MINNEAPOLIS, January 22, 2015 -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 third quarter ended December 31, 2014. Global revenue for the Company’s Urgent ® PC Neuromodulation System grew 14.5% to $4.4 million, a new quarterly revenue record, as compared to $3.9 million in the third quarter of the prior year. Global Macroplastique sales were $2.0 million during the third quarter as compared to $2.3 million in the third quarter of fiscal 2014. Total revenue for the third quarter of fiscal 2015 was $6.7 million, a 4.2% increase from the same quarter in the prior year. The impact of changes in foreign currency exchange rates negatively imp..."
12/22/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, among Vision-Sciences, Inc., Visor Merger Sub LLC and Uroplasty, Inc.* (filed herewith)",
"Voting Agreement, between Uroplasty, Inc. and certain shareholders of Vision-Sciences, Inc. (filed herewith)",
"MINNEAPOLIS, MN & ORANGEBURG, NY, December 22, 2014 – Uroplasty, Inc. and Vision-Sciences, Inc. entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50 million for the fiscal year beginning April 1, 2015. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, each outstanding share of Uroplasty’s common stock will be exchanged for 3.6331 shares of Vision-Sciences’ common stock. Upon completion of the merger, Uroplasty shareholders will own 62.5% of the shares of the combined company on a fully-diluted basis, and Vision-Sciences shareholders will own 37.5%. 1 Following the closing of the transaction, which..."
10/24/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and Release of Claims between Uroplasty, Inc. and Susan H. Holman (filed herewith)"
10/23/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Non-GAAP Financial Measures"
10/15/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "MINNEAPOLIS, MN, October 15, 2014 – Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that Kenneth H. Paulus has been appointed to the Company’s Board of Directors effective October 15, 2014. Mr. Paulus will chair the Board’s compensation committee and serve on the nominating committee."
10/03/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Amendment to Employment Agreement between Uroplasty, Inc. and Darin Hammers",
"Form of Performance Award Agreement pursuant to the Uroplasty, Inc. 2006 Stock and Incentive Plan, as amended"
08/22/2014 8-K Submission of Matters to a Vote of Security Holders
07/24/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Non-GAAP Financial Measures"
06/03/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Employment Agreement between Uroplasty, Inc. and Robert C. Kill (filed herewith)"
06/02/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "MINNEAPOLIS, June 2, 2014 /PRNewswire/ -- Uroplasty, Inc. a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Kevin H. Roche has been appointed to the Company’s Board of Directors effective May 29, 2014. Mr. Roche will chair the Nominating Committee and also serve as a member of Uroplasty’s Audit Committee."
05/28/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/21/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and Release of Claims between Uroplasty, Inc. and Nancy A. Kolb (filed herewith)"
05/15/2014 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Non-GAAP Financial Measures"
01/23/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. to non-GAAP financial measures that exclude non-cash charges for share-based compensation, depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, nor superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparab..."
01/09/2014 8-K Regulation FD Disclosure
10/24/2013 8-K Form 8-K - Current report
08/12/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement between Uroplasty, Inc. and Brett A Reynolds",
"MINNEAPOLIS, MN, August 12, 2013 – Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced the appointment of Brett A. Reynolds as Senior Vice President and Chief Financial Officer. He joins Uroplasty following 10 years in senior positions, including Chief Financial Officer, with Synovis Life Technologies, a Twin Cities based medical device manufacturer acquired by Baxter International last year. “Brett’s significant industry operational experience and proven public company financial leadership will be a valuable asset to Uroplasty. His track record of building strong financial organizations and processes expands the depth of our executive leadership team and we are delight..."
05/30/2013 8-K Quarterly results
Docs: "UROPLASTY REPORTS FISCAL FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS"
09/17/2012 8-K Submission of Matters to a Vote of Security Holders
10/03/2011 8-K Form 8-K - Current report
04/26/2011 8-K Form 8-K - Current report
01/10/2011 8-K Form 8-K - Current report
12/08/2010 8-K Form 8-K - Current report
09/20/2010 8-K Form 8-K - Current report
07/22/2010 8-K Form 8-K - Current report
03/04/2010 8-K Form 8-K - Current report
02/01/2010 8-K Form 8-K - Current report
11/20/2009 8-K Form 8-K - Current report
11/02/2009 8-K Quarterly results
Docs: "UROPLASTY REPORTS RESULTS FOR SECOND QUARTER FY2010"
06/04/2009 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy